Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Patricia Pasquinelli"'
Autor:
Missak Haigentz, Tianhong Li, Mimi Kim, Primo N. Lara, Huiyu Wen, Laurel A. Beckett, Bilal Piperdi, Xianhong Xie, Srikanth Gajavelli, Kaili Zhou, William V. Walsh, Patricia Pasquinelli, Meera Sreedhara, Roman Perez-Soler, Venu Bathini, David R. Gandara, Rasim Gucalp
Publikováno v:
Clinical lung cancer, vol 18, iss 1
Li, T; Piperdi, B; Walsh, WV; Kim, M; Beckett, LA; Gucalp, R; et al.(2017). Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer. Clinical Lung Cancer, 18(1), 60-67. doi: 10.1016/j.cllc.2016.10.003. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8v79g597
Li, T; Piperdi, B; Walsh, WV; Kim, M; Beckett, LA; Gucalp, R; et al.(2017). Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer. Clinical Lung Cancer, 18(1), 60-67. doi: 10.1016/j.cllc.2016.10.003. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8v79g597
© 2016 This randomized phase 2 study demonstrated promising clinical synergism between pemetrexed and intercalated erlotinib in patients with unselected nonsquamous non–small-cell lung cancer (NSCLC) as second-line therapy. EGFR (epidermal growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc695b9f3ff6d72a8b7af4e2f474fd91
https://escholarship.org/uc/item/8v79g597
https://escholarship.org/uc/item/8v79g597
Autor:
Bilal Piperdi, Laurel A. Beckett, Xiaoxia Wu, Primo N. Lara, Mimi Y. Kim, Patricia Pasquinelli, Srikanth Gajavelli, Rasim Gucalp, David R. Gandara, William V. Walsh, Missak Haigentz, Meera Sreedhara, Venu Bathini, Tianhong Li, Roman Perez-Soler
Publikováno v:
Journal of Clinical Oncology. 31:8097-8097
8097 Background: Preclinical and phase I studies showed that PDS optimizes cytotoxicity of concurrent EGFR inhibitors and chemotherapy. We conducted a randomized phase II trial to assess relative efficacy of Pem alone (Arm A) versus Pem +Erl on a PDS
Autor:
R. deere White, Paramita M. Ghosh, Laurel A. Beckett, Jennifer Marie Suga, Chong-Xian Pan, Patricia Pasquinelli, P. N. Lara
Publikováno v:
Journal of Clinical Oncology. 28:e15131-e15131
e15131 Background: Multiple signaling pathways are involved in the development of CRPC. We previously showed that the mTOR pathway is activated in CRPC cell lines while inhibition of this pathway r...
Autor:
Laurel A. Beckett, Patricia Pasquinelli, Chong-Xian Pan, Yu Wang, Hongyong Zhang, Ralph W deVere White, Paramita M. Ghosh, Primo N. Lara
Publikováno v:
Cancer Research. 70:3720-3720
Background: Multiple signaling pathways are involved in the development of CRPC. We previously showed that the mTOR pathway is activated in CRPC cell lines while inhibition of this pathway results in upregulation of androgen receptor (AR) signaling (